What is UroGen Pharma's PP&E (net)?

UroGen Pharma (URGN) reported PP&E (net) of $616K in Q1 2026.

How has UroGen Pharma's PP&E (net) changed year-over-year?

UroGen Pharma's PP&E (net) decreased by 1.8% year-over-year, from $627K to $616K.

What is the long-term trend for UroGen Pharma's PP&E (net)?

Over 5 years (2020 to 2025), UroGen Pharma's PP&E (net) has grown at a -20.8% compound annual growth rate (CAGR), from $2.05M to $637K.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

UroGen Pharma URGN PP&E (Net)

PP&E (Net) at other companies

Bristol-Myers SquibbBMY

$7.66B+6.2%

PfizerPFE

$19.4B+5.8%

Johnson & JohnsonJNJ

$23.27B+11.5%

Merck & Co.MRK

$25.43B+2.6%

ImmunityBio, Inc.IBRX

$112.79M-16.6%

Tyra Biosciences, Inc.TYRA

$1.22M-20.2%

Other financials

Income statement

See full

Revenue$51.0M+152%

Gross profit$11.6M—

Operating income-$22.8M—

Net income-$23.6M+46.2%

EPS (diluted)-$1.17—

Balance sheet

See full

Cash & equivalents$110.0M+5.7%

Total debt$197.1M+56.0%

Total equity-$124.3M-167%

Total assets$253.7M+2.5%

Cash flow

See full

Operating cash flow-$45.3M-7.8%

CapEx$54.0K+22.7%

Free cash flow-$45.4M-7.8%

Valuation

See full

Market cap$1.73B+71.7%

Enterprise value$1.81B+80.9%

P/S12.3×+1.3×

Profitability

See full

Gross margin89.7%—

Operating margin-329.7%—

Net margin-94.8%-25.6pp

FCF margin-118.2%+1.3pp

Returns & leverage

See full

Return on equity-211.6%—

Debt / equity4.8×—

Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is UroGen Pharma's PP&E (net)?: UroGen Pharma (URGN) reported PP&E (net) of $616K in Q1 2026.
How has UroGen Pharma's PP&E (net) changed year-over-year?: UroGen Pharma's PP&E (net) decreased by 1.8% year-over-year, from $627K to $616K.
What is the long-term trend for UroGen Pharma's PP&E (net)?: Over 5 years (2020 to 2025), UroGen Pharma's PP&E (net) has grown at a -20.8% compound annual growth rate (CAGR), from $2.05M to $637K.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.